Results for diclofenac translation from English to Maltese

diclofenac
diclofenac (n=16483)

diclofenac cmax  114%
diclofenac cmax 114

diclofenac auc0-∞  78%
diclofenac auc 78

diclofenac (50 mg single dose)
diclofenac (doża waħda ta’ 50 mg)

150 mg diclofenac in medal oa cohort).
150 mg diclofenac fil- ko- orti oa ta ’ medal).

diclofenac, a medicine used to treat joint pain and inflammation.
diclofenac, mediċina użata biex tittratta uġigħ jew infjammazzjoni fil-ġogi.

examples of nsaids are: acetylsalicylic acid, ibuprofen, ketoprofen, diclofenac.
eżempji ta’ nsaids huma: acetylsalicylic acid, ibuprofen, ketoprofen, diclofenac.

ibuprofen, diclofenac sodium and naproxen) may irritate the stomach and intestine.
diclofenac sodium u naproxen) jistgħu jirritaw l- istonku u l- imsaren.

gastrointestinal and hepatic adverse events were observed significantly more frequently with diclofenac than etoricoxib.
episodji gastrointestinali u epatiċi avversi ġew osservati b’ mod ferm aktar frekwenti b’ diclofenac milli b’ etoricoxib.

there was no significant difference between etoricoxib and diclofenac in the rate of cardiovascular thrombotic events.
ma kien hemm ebda differenza sinjifikanti bejn etoricoxib u diclofenac fir- rata ta ’ episodji trombotiċi kardjovaskulari.

drug interaction studies in healthy adults demonstrated no pharmacokinetic interactions between sodium oxybate and diclofenac.
studji fl-interazzjoni tal-mediċini f’adulti b’saħħithom ma wrewx interazzjonijiet bejn sodium oxybate and diclofenac.

cv mortality, as well as overall mortality, was similar between the etoricoxib and diclofenac treatment groups.
24 il- mortalità cv, kif ukoll il- mortalità in ġenerali, kienet simili bejn il- grupp bil- kura b’ etoricoxib u dak bil - kura b’ diclofenac

ibuprofen, diclofenac, ketorolac or other medicines - used to treat pain and swelling in arthritis and other illnesses
ibuprofen, diclofenac, ketorolac jew mediċini oħrajn - użati sabiex jikkuraw l-uġigħ u n-nefħa fl- artrite u mard ieħor

21 diclofenac 150 mg but was higher for etoricoxib 90 mg compared to diclofenac 150 mg (statistically significant for 90 mg etoricoxib vs.
l- inċidenza ta ’ episodji avversi ta ’ kollass konġestiv tal- qalb (twaqqif u episodji serji) seħħew f’ rati simili fuq etoricoxib 60 mg meta mqabbel ma ’ diclofenac 150 mg iżda kienet ogħla għal etoricoxib 90 mg meta mqabbel ma ’ diclofenac 150 mg (statistikament sinjifikanti għal 90 mg etoricoxib vs.

a771726 displaced ibuprofen, diclofenac and tolbutamide but the unbound fraction of these drugs is only increased by 10 % to 50 %.
a771726 jisposta lil ibuprofen, lil diclofenac u lil tolbutamide, iżda l-parti mhux marbuta ta’ dawn il-mediċini tiżdied biss b’10% sa 50 %.

a771726 displaced ibuprofen, diclofenac and tolbutamide but the unbound fraction of these medicinal products is only increased by 10% to 50%.
a771726 jisposta lil ibuprofen, lil diclofenac u lil tolbutamide, iżda l-parti mhux marbuta ta’ dawn il-mediċini tiżdied biss b’10% sa 50%.

for the subset of upper gi hemorrhage events (complicated and uncomplicated combined), there was no significant difference between etoricoxib and diclofenac.
għas - subsett ta ’ episodji ta ’ emorraġija gi ta ’ fuq (ikkumplikati u mhux ikkumplikati flimkien), ma kien hemm ebda differenza sinjifikanti bejn etoricoxib u diclofenac.

cardiorenal adverse events were observed more frequently with etoricoxib than with diclofenac, and this effect was dose-dependent (see specific results below).
episodji kardjorenali avversi ġew osservati b’ mod aktar frekwenti b’ etoricoxib aktar milli b’ diclofenac, u dan l- effett kien dipendenti fuq id- doża (ara r- riżultati speċifiċi taħt).

there was little direct comparative safety data for individual non-steroidal anti-inflammatory drugs (nsaids) other than diclofenac and naproxen.
kien hemm ftit dejta dwar is- sigurtà li setgħet titqabbel direttament għal mediċini antinfjammatorji mhux sterojdali individwali (nsaid) minbarra diclofenac u naproxen.

the upper gi benefit for etoricoxib compared with diclofenac was not statistically significant in patients taking concomitant low-dose aspirin (approximately 33% of patients).
il- benefiċċju gi ta ’ fuq għal etoricoxib meta mqabbel ma ’ diclofenac ma kienx statistikament sinjifikanti f’ pazjenti li kienu qegħdin jieħdu aspirina ta ’ doża baxxa fl- istess ħin (bejn wieħed u ieħor 33% tal- pazjenti).